Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia
A Study to Test if TV-46000 is Effective for Maintenance Treatment of Schizophrenia
Sponsor:Teva Branded Pharmaceutical Products R&D, Inc.
Enrolling:Male and Female Patients
Age Range:Between 18 and 65 years old
IRB Number:7685
U.S. Government ID:NCT03503318
Contact: Marlene Carlson, MPH: 646-774-8436 /
Additional Study Information:

The purpose of this study is to evaluate the efficacy, safety and tolerability of different doses and durations of TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance in adults with schizophrenia.

Do You Qualify?
Do you have schizophrenia?YesNo
Are you between the ages of 18 - 55?YesNo
Are you / have you been on Clozapine?YesNo
Joshua Kantrowitz, MD
You may be eligible for this study

Place Holder

Who Can I Contact?
For more information, please contact:
Marlene Carlson, MPH
Phone: 646-774-8436